Equities

Vivesto AB

Vivesto AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.283
  • Today's Change-0.007 / -2.25%
  • Shares traded444.40k
  • 1 Year change-33.49%
  • Beta0.9763
Data delayed at least 15 minutes, as of Apr 26 2024 12:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-128.75m
  • Incorporated1988
  • Employees14.00
  • Location
    Vivesto ABGustav III:s Boulevard 46, 5trSOLNA 169 73SwedenSWE
  • Phone+46 18505440
  • Fax+46 18510873
  • Websitehttps://www.vivesto.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biovica International AB5.98m-122.99m124.77m37.00--0.9911--20.87-2.42-2.420.1151.620.033-0.30538.43170,800.00-67.80-42.10-74.69-46.33110.09277.88-2,057.41-2,149.687.10--0.057--65.434.44-84.14---20.20--
New Nordic Healthbrands AB533.85m-6.20m125.14m73.00--1.18--0.2344-1.00-1.0086.1717.112.131.724.897,313,014.00-2.475.36-5.5510.5565.2367.30-1.162.380.8906-1.150.213847.969.516.28-119.41--28.36--
AlzeCure Pharma AB0.00-37.17m127.28m11.00--5.35-----0.5986-0.59860.000.38290.00----0.00-72.28-52.78-88.22-57.01------------0.00------33.91------
Bactiquant A/S19.28m-20.53m129.96m----5.76--6.74-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
SoftOx Solutions AS6.94m-41.82m132.39m--------19.09-1.98-1.980.3286-0.01270.081--1.60---48.81-50.83-82.20-64.58-----602.91-646.670.1745-3.45-----1.8810.0640.85--39.43--
Enorama Pharma AB1.22m-43.96m138.12m----5.80--113.40-2.16-2.160.04230.43090.03061.070.3212---110.45-64.94-277.27-94.45-267.0886.49-3,609.52-405.420.7249--0.023---37.9634.20-51.50------
ExpreS2ion Biotech Holding AB8.80m-95.99m140.85m28.00--2.31--16.01-2.12-2.120.18951.190.0832--9.91---90.72-64.80-113.72-77.46-109.74-1.94-1,090.91-532.25----0.0045--43.07-0.156119.07--19.90--
StenoCare A/S5.89m-27.53m143.74m9.00--3.51--24.41-1.29-1.290.2711.420.0967--1.25417,535.60-45.21-28.15-63.19-35.47-----467.55-371.061.30-5.540.2727---16.30---7.77------
Vo2 Cap Holding AB (publ)344.97m5.56m151.89m--27.280.6764.050.44030.10410.10416.534.200.7076--5.39--1.14-0.25641.58-0.383934.7823.361.61-0.2409--6.130.1628---26.0985.65-57.92---17.96--
SenzaGen AB49.87m-22.10m153.84m34.00--2.28--3.08-0.9136-0.91362.062.800.45943.044.031,466,765.00-20.35-25.84-27.59-29.8570.0568.62-44.31-132.291.22--0.0242--19.3990.3211.30---21.10--
Xintela AB78.00k-54.09m155.36m----35.47--1,991.79-0.1524-0.15240.00020.00770.0036--0.0088---252.09-181.06-1,065.04-391.61100.00---69,343.59-235,894.00---50.470.00-----45.5418.32---61.47--
Vivesto AB0.00-128.75m155.76m14.00--0.7875-----0.2414-0.24140.000.36760.00----0.00-45.24---49.14-------------------100.00--64.80------
PMD Device Solutions AB10.21m-28.81m165.75m1.00------16.24-60.60-60.6021.39-204.840.3345--4.93---94.42-------29.08---282.27--0.0568-6.50----------------
Kancera AB0.00-64.89m175.48m3.00---------0.786-0.7860.00--------0.00---54.82---66.21-------7,249.06-------------23.64------
InDex Pharmaceuticals Holding AB97.51m-95.27m186.44m7.00--0.7805--1.91-0.1766-0.17660.18250.44850.2997----13,929,290.00-29.28-37.64-33.02-41.14-82.02-450.51-97.70-454.62----0.0095----277.025.05------
Active Biotech AB publ0.00-45.80m192.81m11.00--6.29-----0.172-0.1720.000.08480.00-------96.37-57.97-126.15-97.83-------1,454.61----0.1291------21.54------
Data as of Apr 26 2024. Currency figures normalised to Vivesto AB's reporting currency: Swedish Krona SEK

Institutional shareholders

1.64%Per cent of shares held by top holders
HolderShares% Held
SEB Investment Management ABas of 28 Mar 20243.13m0.58%
Handelsbanken Fonder ABas of 31 Mar 20242.74m0.51%
Skandia Investment Management ABas of 29 Feb 20242.40m0.45%
Storebrand Asset Management ASas of 31 Jan 2024439.70k0.08%
Case Kapitalf�rvaltning ABas of 30 Nov 202295.83k0.02%
Evli Fund Management Co. Ltd.as of 28 Mar 202428.66k0.01%
FCG Fonder ABas of 31 Oct 20230.000.00%
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.